Novavax Inc. Stock Underperforms Friday When Compared To Competitors

Nuveen California Municipal Value Fund

Change company Symbol lookup

Select an option...

NCA Nuveen California Municipal Value Fund

SGOL abrdn Physical Gold Shares ETF

GAB-K Gabelli Equity Trust Inc

GAB-H Gabelli Equity Trust Inc

GAB-G Gabelli Equity Trust Inc

AAL American Airlines Group Inc

ARKF ARK Fintech Innovation ETF

PNR Pentair PLC

AMD Advanced Micro Devices Inc

IDAI T Stamp Inc

Company profile

Nuveen California Municipal Value Fund, Inc. (the Fund) is a diversified, closed-end management investment company. The Fund's objective is to seeks current income exempt from both regular federal income taxes and California personal income tax. Its secondary investment objective is the enhancement of portfolio value. The Fund invests in municipal securities that are exempt from federal and California state income taxes. The Fund invests at least 80% of its managed assets in securities rated, at the time of investment, investment grade or, if they are unrated, are judged by the manager to be of comparable quality. The Fund also invest up to 20% of its managed assets in municipal securities rated below investment quality or judged by the manager to be of comparable quality, of which up to 10% of its managed assets may be rated below B-/B3 or of comparable quality. It also invests in inverse floating rate municipal securities. Its investment adviser is Nuveen Fund Advisors, LLC.

Novavax Inc. Stock Underperforms Friday When Compared To Competitors

5:15 pm ET January 6, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Novavax Inc. (NVAX) slipped 5.89% to $11.02 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index rising 2.56% to 10,569.29 and the Dow Jones Industrial Average rising 2.13% to 33,630.61. The stock's fall snapped a two-day winning streak. Novavax Inc. closed $126.64 short of its 52-week high ($137.66), which the company achieved on January 10th.

The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) rose 0.81% to $180.25, Pfizer Inc. (PFE) rose 2.54% to $50.92, and Merck & Co. Inc. (MRK) rose 1.06% to $114.84. Trading volume (6.4 M) remained 72,785 below its 50-day average volume of 6.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 6, 2023.

(END) Dow Jones Newswires

January 06, 2023 17:15 ET (22:15 GMT)